Remicade Biosimilar Market Expansion to $10.89 Billion by 2029: Key Drivers and Trends

Uncover key drivers, emerging technologies, and competitive movements shaping the remicade biosimilar market from 2025–2034 with trusted insights from The Business Research Company

What Is The Base Market Size For The Remicade Biosimilar Market Today And What Will It Reach By 2029?

The remicade biosimilar market size has experienced rapid expansion in recent years. This market is anticipated to increase from $3.95 billion in 2024 to reach $4.89 billion in 2025, progressing at a compound annual growth rate (CAGR) of 23.8%. Key drivers for this growth during the historic period include the initial introduction of remicade (infliximab), coupled with significant biotechnology advancements, the expiration of biologics patents, the establishment of clear regulatory pathways, and ongoing healthcare cost pressures.

The remicade biosimilar market is projected to experience substantial expansion over the upcoming years. Its valuation is anticipated to reach $10.89 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 22.2%. This growth during the forecast period stems from factors such as patent expirations, an increasing need for affordable treatments, advancements in biosimilar pipeline development, supportive reimbursement policies, and market consolidation. Key trends identified for the forecast period encompass physician prescribing behavior, biosimilar lifecycle management, biosimilar naming conventions, biosimilar interchangeability, and biosimilar real-world evidence.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11952&type=smp

What Factors Are Boosting The Remicade Biosimilar Market?

The increasing occurrence of autoimmune conditions is anticipated to drive the expansion of the remicade biosimilar market in the future. These conditions are characterized by the immune system erroneously attacking and harming the body’s own tissues and organs. Remicade biosimilars offer an effective treatment solution for autoimmune diseases, helping to manage symptoms and lessen the accompanying inflammation. As an illustration, data from Public Health Scotland, a Scotland-based national organization, revealed in July 2023 that the percentage of newly diagnosed multiple sclerosis (MS) patients rose to 87.2% in 2022, an increase from 85.7% in 2020. This included 491 new cases, bringing the overall count to 6,359 in 2022. Consequently, the growing prevalence of autoimmune diseases is stimulating the expansion of the remicade biosimilar market.

How Is The Remicade Biosimilar Market Categorized By Application, Type, And Region?

The remicade biosimilar market covered in this report is segmented –

1) By Type: 100mg/10ml, 500mg/50ml

2) By Disease Indication: Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Psoriatic Arthritis, Plaque Psoriasis

3) By Application: Blood Disorders, Oncology Diseases

Subsegments:

1) By 100 Mg/10 Ml: Vials For Injection, Prefilled Syringes

2) By 500 Mg/50 Ml: Vials For Injection, Prefilled Syringes

How Are Technological Trends Affecting The Remicade Biosimilar Market Growth?

A significant and growing trend in the Remicade biosimilar market is product innovation. Prominent companies operating in this sector are actively developing novel products to uphold their market standing. For instance, Amgen Inc., a biotechnology company based in the US, introduced Amjevita in January 2023 in the US. This product is a biosimilar variant of AbbVie’s Humira, engineered to be as safe and effective as the original drug. Amjevita holds the distinction of being the first biosimilar to Humira and is projected to vie for market share against it. Humira, a biological drug, is prescribed for various autoimmune diseases, including rheumatoid arthritis and Crohn’s disease. It ranks among the world’s most expensive drugs, annually generating billions of dollars in sales for AbbVie. In contrast, Amjevita is anticipated to be significantly more affordable. Furthermore, besides financial savings, Amjevita offers patients additional treatment pathways.

Who Are The Global Leaders Steering The Remicade Biosimilar Market Forward?

Major companies operating in the remicade biosimilar market include Novartis AG, Amgen Inc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Merck And Co. Inc., LG Chem Ltd., Nippon Kayaku Co. Ltd., Celltrion Inc., Nichi-iko Pharmaceutical Co. Ltd., Biocon Limited, Alvotech S.A., MabPharm Ltd., Genor Biopharma Co. Ltd, Shanghai Biomabs Pharmaceuticals Co. Ltd., Samsung Bioepis Co. Ltd., Biocad Biopharmaceutical Co, EPIRUS Biopharmaceuticals Inc., Ranbaxy Laboratories Limited, BioXpress Therapeutics SA, Mabion S.A

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/remicade-biosimilar-global-market-report

Which Region Is Projected To Achieve The Fastest Growth In The Remicade Biosimilar Market?

Europe was the largest region in the remicade biosimilar market in 2024. The regions covered in the remicade biosimilar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=11952&type=smp

Browse Through More Reports Similar to the Global Remicade Biosimilar Market 2025, By The Business Research Company

Biostimulants Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biostimulants-global-market-report

Agroscience Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/agroscience-global-market-report

Agricultural Biologics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/agricultural-biologics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795